STOCK TITAN
  1. Home
  2. SEC Filings
  3. VICR
  4. [144] VICOR CORP SEC Filing

Patrizio Vinciarelli reports multiple share sales

Patrizio Vinciarelli reported multiple resale sales of Common stock under 10b5-1 arrangements.

Filing Impact
(Neutral)
Filing Sentiment

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment worksHow the balance works

Form Type
144

Rhea-AI Filing Summary

Patrizio Vinciarelli reported multiple resale sales of Common stock under 10b5-1 arrangements. The filing lists repeated 10b5-1 transactions in 2026, including a 06/11/2026 sale of 20,000 shares for $5,807,751.00 and an 04/15/2026 sale of 50,000 shares for $9,660,511.00. The entries enumerate numerous additional dated trades and several institutional entries for smaller blocks.

Insights

Multiple scheduled 10b5-1 dispositions by a single reporting person are recorded.

The excerpt lists numerous dated 10b5-1 sales by Patrizio Vinciarelli, with many multi‑thousand‑share trades across 03/2026–06/2026. These entries appear as routine, prearranged dispositions rather than ad‑hoc open‑market decisions.

Cash‑flow treatment and remaining holdings are not shown in the excerpt; subsequent filings may provide post‑transaction positions and further context.

Sample sale 06/11/2026 20,000 shares sale for $5,807,751.00 on 06/11/2026
Sample sale 04/15/2026 50,000 shares sale for $9,660,511.00 on 04/15/2026
Smaller institutional entry 3,500 shares Brigham and Women's Hospital sale for $1,043,623.00 on 05/14/2026
Repeated block size 50,000 shares multiple 50,000‑share 10b5-1 sales in March–April 2026
Example mid‑June sale 20,000 shares sale for $5,807,751.00 on 06/11/2026 (example of June activity)
10b5-1 regulatory
"10b5-1 Sales for PATRIZIO VINCIARELLI 25 Frontage Road Andover MA"
A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.
Form 144 regulatory
"144: Securities Sold During The Past 3 Months"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.
Resale financial
"Securities To Be Sold ... Founders Shares ... Issuer"
Resale is the act of selling an item, asset, or security by someone who previously bought it rather than by the original maker or issuer. It matters to investors because resale activity affects how easily an investment can be sold, the price buyers are willing to pay, and the potential profit or loss — like selling a used car: condition, demand and market rules determine what you can get for it.
Common financial
"Common | Morgan Stanley Smith Barney LLC Executive Financial Services"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does VICR's Form 144 show about recent insider activity?
The Form 144 reports multiple resale sales by Patrizio Vinciarelli under 10b5-1 arrangements. Examples include a 06/11/2026 sale of 20,000 shares for $5,807,751.00 and a 04/15/2026 sale of 50,000 shares for $9,660,511.00.

Are the trades in the VICR excerpt part of a 10b5-1 plan?
Yes. Many entries are labeled as 10b5-1 Sales, indicating prearranged trading plans. The excerpt lists dates and share amounts tied to those 10b5-1 transactions but does not include plan adoption dates or detailed plan terms.

How large were individual trades reported in VICR's filing?
Reported individual trades range from blocks of 3,500 shares to 50,000 shares. Examples in the excerpt include 05/14/2026 sales of 3,500 shares and multiple 50,000 share sales in March–April 2026.

Does the Form 144 excerpt state remaining holdings or proceeds use for VICR?
The excerpt lists sale amounts and gross proceeds for each trade but does not state remaining holdings or the use of proceeds. Post‑transaction positions and specific cash‑flow recipients are not provided in the visible text.

Which parties appear as sellers besides the individual in the VICR excerpt?
The excerpt lists institutional names such as Brigham and Women's Hospital and Lahey Hospital & Medical Center with specific dated common stock entries. These appear alongside the individual 10b5-1 sales in the same table.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Accepted by SEC EDGAR

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Source: View Original Filing on SEC EDGAR

Keep reading

More on VICR

All VICR news

Trending in the feed

LQDA
Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH Open the live feed